Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: Results of ARC001, A randomized, double-blind, placebo-controlled phase 2 clinical trial

Veena Agusala; Brooke I. Polk; Chitra Dinakar

doi:10.1542/peds.2018-2420CCC

Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: Results of ARC001, A randomized, double-blind, placebo-controlled phase 2 clinical trial

Veena Agusala, Brooke I. Polk, Chitra Dinakar

Division of Allergy & Pulmonary Medicine

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Original language	English
Pages (from-to)	S242
Journal	Pediatrics
Volume	142
DOIs	https://doi.org/10.1542/peds.2018-2420CCC
State	Published - Dec 2018

Access to Document

10.1542/peds.2018-2420CCC

Cite this

@article{ee135d6aa4d94a8fa11d5d5dba722ffa,

title = "Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: Results of ARC001, A randomized, double-blind, placebo-controlled phase 2 clinical trial",

author = "Veena Agusala and Polk, {Brooke I.} and Chitra Dinakar",

year = "2018",

month = dec,

doi = "10.1542/peds.2018-2420CCC",

language = "English",

volume = "142",

pages = "S242",

journal = "Pediatrics",

issn = "0031-4005",

}

TY - JOUR

T1 - Efficacy and safety of AR101 in oral immunotherapy for peanut allergy

T2 - Results of ARC001, A randomized, double-blind, placebo-controlled phase 2 clinical trial

AU - Agusala, Veena

AU - Polk, Brooke I.

AU - Dinakar, Chitra

PY - 2018/12

Y1 - 2018/12

UR - http://www.scopus.com/inward/record.url?scp=85057836916&partnerID=8YFLogxK

U2 - 10.1542/peds.2018-2420CCC

DO - 10.1542/peds.2018-2420CCC

M3 - Comment/debate

AN - SCOPUS:85057836916

SN - 0031-4005

VL - 142

SP - S242

JO - Pediatrics

JF - Pediatrics

ER -

Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: Results of ARC001, A randomized, double-blind, placebo-controlled phase 2 clinical trial

Access to Document

Other files and links

Cite this